CN Patent
CN103889987A — 作为btk-抑制剂的4-咪唑并哒嗪-1-基-苯甲酰胺类和4-咪唑并三嗪-1-基-苯甲酰胺类
Assigned to Merck Sharp and Dohme BV · Expires 2014-06-25 · 12y expired
What this patent protects
本发明涉及式I的6-5元稠合吡啶环化合物 或其药学上可接受的盐或涉及含有这类化合物的药物组合物以及涉及它们在治疗中的用途。本发明特别涉及式I的6-5元稠合吡啶环化合物在治疗布鲁顿酪氨酸激酶(Btk)介导的病症中的用途。
USPTO Abstract
本发明涉及式I的6-5元稠合吡啶环化合物 或其药学上可接受的盐或涉及含有这类化合物的药物组合物以及涉及它们在治疗中的用途。本发明特别涉及式I的6-5元稠合吡啶环化合物在治疗布鲁顿酪氨酸激酶(Btk)介导的病症中的用途。
Drugs covered by this patent
- Calquence (ACALABRUTINIB) · AstraZeneca
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.